Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results

Rhea-AI Summary

Rafael Holdings (NYSE: RFL) reported Q3 fiscal 2025 financial results, highlighting its recent merger with Cyclo Therapeutics. The company reported a net loss of $4.8 million ($0.19 per share) for Q3, compared to $32.4 million ($1.36 per share) in the previous year. Cash position stood at $37.9 million as of April 30, 2025, further strengthened by a recent $25 million rights offering. The company anticipates topline data from the fully enrolled Phase 3 TransportNPC™ trial of Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 later this month. R&D expenses increased to $3.0 million from $1.5 million, while G&A expenses rose to $3.2 million from $1.9 million, primarily due to the Cyclo Therapeutics merger and consolidation of Cornerstone and Day Three operations.

Positive

• Successfully completed merger with Cyclo Therapeutics, expanding therapeutic pipeline
• Strengthened financial position with $25 million rights offering, raising net proceeds of $24.9 million
• Significant reduction in net loss to $4.8 million from $32.4 million year-over-year
• Healthy cash position of $37.9 million as of April 30, 2025

Negative

• Increased R&D expenses to $3.0 million from $1.5 million year-over-year
• Higher G&A expenses at $3.2 million compared to $1.9 million in previous year
• Continued net loss position of $4.8 million in Q3
• Unrealized losses of $1.4 million on Cyclo equity investment

Insights

Biotechnology and Financial Analyst

Rafael Holdings reports Q3 loss of $4.8M while anticipating crucial Phase 3 results for rare disease treatment following Cyclo Therapeutics merger.

Rafael Holdings has positioned itself at a pivotal juncture with the completed merger with Cyclo Therapeutics and an imminent data readout from a significant clinical trial. The company is expecting topline data from the 48-week interim analysis of the TransportNPC™ Phase 3 study later this month, which evaluates Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 - a rare and fatal genetic disorder with limited treatment options.

The company has substantially strengthened its financial position through a $25 million rights offering that closed on June 4, yielding net proceeds of $24.9 million. This capital infusion, combined with existing cash reserves of $37.9 million as of April 30, provides Rafael with approximately $62.8 million in available funds to support continued clinical development.

For Q3 fiscal 2025, Rafael reported a net loss of $4.8 million ($0.19 per share), a significant improvement from the $32.4 million loss ($1.36 per share) in the comparable period. This 85% reduction in net loss was primarily due to non-recurring charges in the prior year related to the Cornerstone acquisition.

The merger with Cyclo Therapeutics has expectedly increased operational expenses, with R&D costs rising to $3 million from $1.5 million year-over-year, and G&A expenses increasing to $3.2 million from $1.9 million. These increases reflect the expanded operations following the merger and consolidation with Cornerstone and Day Three.

The upcoming clinical trial results represent a critical inflection point for Rafael Holdings. Niemann-Pick Disease Type C1 is an ultra-rare condition with a significant unmet medical need. Positive efficacy data could potentially position Trappsol® Cyclo™ as one of the few treatment options for this devastating disease, which would substantially enhance Rafael's clinical and commercial prospects in the orphan drug space.

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected later this month

NEWARK, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT), today reported its financial results for the third quarter and first nine months of fiscal year 2025 ended April 30, 2025.

“We are pleased to have completed our merger with Cyclo Therapeutics and look forward to reporting the topline data from the 48-week interim analysis of the pivotal Phase 3 TransportNPC™ study evaluating Trappsol^® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 anticipated later this month,” said Howard Jonas, Chief Executive Officer, Executive Chairman and Chairman of the Board of Rafael Holdings. Mr. Jonas added, “We have enhanced our financial position with the closing of a $25 million rights offering earlier this month which will support advancing this potential new treatment option for patients suffering from this rare genetic disease.”

Rafael Holdings, Inc. Third Quarter Fiscal Year 2025 Financial Results

As of April 30, 2025, we had cash and cash equivalents of $37.9 million. On June 4, 2025, the Company announced the closing of a $25 million rights offering, which, including the funding of the backstop commitment by the Jonas family, raised net proceeds of $24.9 million after deduction of certain expenses incurred in connection with the offering.

For the three months ended April 30, 2025, we recorded a net loss attributable to Rafael Holdings of $4.8 million, or $0.19 per share, versus a net loss of $32.4 million, or $1.36 per share in the year ago period. The year over year decrease in net loss is attributable to non-cash items, primarily unrealized losses of $1.4 million on the Company’s investment in Cyclo equity which we purchased in advance of the potential merger in the current period versus $4.4 million in the year ago period, combined with an in-process R&D expense of $89.9 million related to the acquisition of Cornerstone, partially offset by a $31.3 million recovery of receivables from Cornerstone in the year ago period.

Research and development expenses were $3.0 million for the three months ended April 30, 2025, compared to $1.5 million in the year ago period. The year over year increase relates to the inclusion in the current year period of spending at Cyclo Therapeutics following the March 25, 2025 merger and the activity of Cornerstone and Day Three which were consolidated with Rafael Holdings during fiscal 2024.

General and administrative expenses were $3.2 million for the three months ended April 30, 2025, compared to $1.9 million in the year ago period. The year over year increase relates to the inclusion of Cyclo Therapeutics following closing of the merger, and the activity of Cornerstone and Day Three, following their consolidation.

Rafael Holdings, Inc. First Nine Months Fiscal Year 2025 Financial Results

For the nine months ended April 30, 2025, we recorded a net loss attributable to Rafael Holdings of $18.4 million, or $0.73 per share, versus a net loss of $29.9 million, or $1.26 per share in the year ago period. The year over year decrease in net loss is attributable to in-process R&D expense of $89.9 million related to the acquisition of Cornerstone net with a $31.3 million recovery of receivables from Cornerstone in the year ago period and $3.2 million in unrealized gains on the Company’s investment in Cyclo equity.

Research and development expenses were $5.3 million for the nine months ended April 30, 2025, compared to $2.6 million in the year ago period. The year over year increase relates to the merger with Cyclo Therapeutics which closed on March 25, 2025, and the activity of Cornerstone and Day Three, which were consolidated with Rafael Holdings during fiscal 2024.

For the nine months ended April 30, 2025, general and administrative expenses were $8.3 million compared to $6.5 million in the same period in the prior year. The year over year increase relates to the merger with Cyclo Therapeutics which closed on March 25, 2025, and the activity of Cornerstone and Day Three, which were consolidated with Rafael Holdings during fiscal 2024.

About Rafael Holdings, Inc.

Rafael Holdings, Inc. holds interests in clinical and early-stage pharmaceutical and certain other companies, including our wholly owned subsidiary, Cyclo Therapeutics, LLC, a clinical stage biotechnology company dedicated to developing Rafael’s lead clinical candidate, Trappsol^® Cyclo™, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 (“NPC1”), a rare, fatal, and progressive genetic disorder. Rafael also holds majority equity interests in LipoMedix Pharmaceuticals Ltd., a clinical stage pharmaceutical company, Cornerstone Pharmaceuticals, Inc., formerly known as Rafael Pharmaceuticals Inc., a cancer metabolism-based therapeutics company, Rafael Medical Devices, LLC, an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries, and Day Three Labs, Inc., a company which empowers third-party manufacturers to reimagine their existing cannabis offerings. 

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; plans regarding the further evaluation of clinical data; and the potential of our pipeline, including our internal cancer metabolism research programs. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, those disclosed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended July 31, 2024, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Contact:
Barbara Ryan
Barbara.ryan@rafaelholdings.com
(203) 274-2825

RAFAEL HOLDINGS, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
		April 30, 2025				July 31, 2024
						(audited)
ASSETS
CURRENT ASSETS
Cash and cash equivalents		$	37,936			$	2,675
Available-for-sale securities			—				63,265
Interest receivable			—				515
Prepaid clinical trial costs			2,968				—
Convertible note receivables, due from Cyclo			—				5,191
Accounts receivable, net of allowance for credit losses of $245 at April 30, 2025 and July 31, 2024			414				426
Inventory			288				—
Prepaid expenses and other current assets			837				430
Total current assets			42,443				72,502
Property and equipment, net			1,614				2,120
Non-current prepaid clinical trial costs			1,399				—
Investments – Cyclo			—				12,010
Investments - Hedge Funds			—				2,547
Convertible note receivable classified as available-for-sale			1,719				1,146
Goodwill			28,278				3,050
Intangible assets, net			1,027				1,847
In-process research and development			31,575				1,575
Other assets			41				35
TOTAL ASSETS		$	108,096			$	96,832
LIABILITIES AND EQUITY
CURRENT LIABILITIES
Accounts payable		$	7,793			$	2,556
Accrued expenses			1,866				1,798
Convertible notes payable			614				614
Other current liabilities			93				113
Due to related parties			664				733
Installment note payable			—				1,700
Total current liabilities			11,030				7,514
Accrued expenses, noncurrent			3,445				2,982
Convertible notes payable, noncurrent			76				73
Other liabilities			25				5
Deferred income tax liability			9,002				—
TOTAL LIABILITIES			23,578				10,574
COMMITMENTS AND CONTINGENCIES
EQUITY
Class A common stock, $0.01 par value; 35,000,000 shares authorized, 787,163 shares issued and outstanding as of April 30, 2025 and July 31, 2024			8				8
Class B common stock, $0.01 par value; 200,000,000 shares authorized, 31,240,188 issued and outstanding (excluding treasury shares of 101,487) as of April 30, 2025, and 24,142,535 issued and 23,819,948 outstanding (excluding treasury shares of 101,487) as of July 31, 2024			312				238
Additional paid-in capital			296,648				280,048
Accumulated deficit			(220,169	)			(201,743	)
Treasury stock, at cost; 101,487 Class B shares as of October 31, 2024 and July 31, 2024			(168	)			(168	)
Accumulated other comprehensive income related to unrealized income on available-for-sale securities			219				111
Accumulated other comprehensive income related to foreign currency translation adjustment			3,728				3,691
Total equity attributable to Rafael Holdings, Inc.			80,578				82,185
Noncontrolling interests			3,940				4,073
TOTAL EQUITY			84,518				86,258
TOTAL LIABILITIES AND EQUITY		$	108,096			$	96,832

RAFAEL HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(unaudited, in thousands, except share and per share data)
	Three Months Ended April 30,								Nine Months Ended April 30,
		2025				2024				2025				2024
Revenues	$	362			$	336			$	567			$	472
Cost of Infusion Technology revenue		31				85				106				85
Cost of product revenue		9				—				9				—
SG&A Expenses		3,170				1,923				8,284				6,524
R&D Expenses		3,003				1,526				5,276				2,627
In-process R&D expense		—				89,861				—				89,861
Depreciation and amortization		62				102				238				157
Loss on impairment of goodwill		—				—				3,050				—
Operating Loss		(5,913	)			(93,161	)			(16,396	)			(98,782	)
Interest income		472				502				1,529				1,777
Loss on initial investment in Day Three upon acquisition		—				—				—				(1,633	)
Realized gain on available-for-sale securities		—				945				178				1,521
Realized loss on investment in equity securities		—				—				—				(46	)
Realized gain on investment - Cyclo		—				—				—				424
Unrealized (loss) gain on investments - Cyclo		(1,393	)			(4,395	)			(5,144	)			3,199
Unrealized gain (loss) on convertible notes receivable, due from Cyclo		383				—				(719	)			—
Unrealized loss on investments - Hedge Funds		—				(3	)			—				(118	)
Recovery of receivables from Cornerstone		—				31,305				—				31,305
Interest expense		(165	)			(85	)			(490	)			(85	)
Other income, net		154				—				74				118
Loss before Incomes Taxes		(6,462	)			(64,892	)			(20,968	)			(62,320	)
Benefit from income taxes		2,411				2,599				2,379				2,593
Equity in loss of Day Three		—				—				—				(422	)
Consolidated net loss		(4,051	)			(62,293	)			(18,589	)			(60,149	)
Net income (loss) attributable to noncontrolling interests		728				(29,942	)			(163	)			(30,207	)
Net loss attributable to Rafael Holdings, Inc.	$	(4,779	)		$	(32,351	)		$	(18,426	)		$	(29,942	)
Loss per share
Basic and diluted		(0.19	)			(1.36	)			(0.73	)			(1.26	)
Loss per basic common share	$	(0.19	)		$	(1.36	)		$	(0.73	)		$	(1.26	)
Weighted average shares in calculation		25,238,501				23,777,493				23,131,655				23,687,781

FAQ

What were Rafael Holdings (RFL) Q3 2025 financial results?

Rafael Holdings reported a Q3 2025 net loss of $4.8 million ($0.19 per share), compared to $32.4 million ($1.36 per share) in the previous year, with cash and equivalents of $37.9 million as of April 30, 2025.

How much did Rafael Holdings (RFL) raise in their recent rights offering?

Rafael Holdings raised $25 million through a rights offering, resulting in net proceeds of $24.9 million after expenses.

What is the status of Rafael Holdings' TransportNPC clinical trial?

The TransportNPC Phase 3 clinical trial for Trappsol® Cyclo™ is fully enrolled, with 48-week interim analysis results expected later in June 2025.

How did Rafael Holdings' operating expenses change in Q3 2025?

R&D expenses increased to $3.0 million from $1.5 million, and G&A expenses rose to $3.2 million from $1.9 million year-over-year, mainly due to the Cyclo Therapeutics merger.

When did Rafael Holdings complete its merger with Cyclo Therapeutics?

Rafael Holdings completed its merger with Cyclo Therapeutics on March 25, 2025.